UBS notes the American Society of Oncology abstracts for the company's FOXFIRE/Gloval study shows overall survival rates were not enhanced by Sir-Spheres.
The abstracts are limited in detail and further sub-group analysis may yet reveal differences. UBS has not taken a view on the outcome and its price target relies on existing indications.
Target is $30.30. Buy retained.
Sector: Pharmaceuticals & Biotechnology.
Target price is $30.30.Current Price is $10.75. Difference: $19.55 - (brackets indicate current price is over target). If SRX meets the UBS target it will return approximately 65% (excluding dividends, fees and charges - negative figures indicate an expected loss).
http://www.*********.com.au/broker_news.asp?a=AV&ai=44055
UBS notes the American Society of Oncology abstracts for the...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.40M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.0¢ | 17.5¢ | $61.98K | 351.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 11238850 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1266857 | 36 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| SRX (ASX) Chart |